Clinical Trials · NCT06065540
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 2,734
- Start date
- Sep 2023
- Locations
- 405 sites, 32 countries
- Primary endpoint
- CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)